{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:35:39Z","timestamp":1775669739681,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Stakeholders met to address persistent challenges facing the development of therapeutics for polyarticular juvenile idiopathic arthritis (pJIA), which result in fewer approved therapies for children with pJIA than adults with rheumatoid arthritis (RA) and long lag times from adult RA approval to pediatric labeling. Ensuring that new medications are authorized in a timely manner to meet the needs of JIA patients worldwide is critically important to multiple stakeholders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Food and Drug Administration in collaboration with the University of Maryland Center for Regulatory Science and Innovation held a public workshop entitled \u201cAccelerating Drug Development for pJIA\u201d on October 2, 2019, to address challenges surrounding access to new medications for children and adolescents with pJIA. Regulatory, academic, and industry stakeholders, as well as patient representatives, participated in the workshop, which consisted of 4 sessions, including panel discussions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The workshop facilitated broad public discussion of challenges facing the development of pJIA therapeutics, highlighting areas of need and outlining opportunities to expedite development, while underscoring the necessity of close collaboration between all stakeholders, including patients and families.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report summarizes key aspects of the workshop, including the appropriate application of innovative approaches to the development of pJIA therapeutics, including extrapolation, to address current challenges and provide timely access to newer safe and effective treatments. Long\u2010term safety assessment is of pressing concern to stakeholders and cannot be fully extrapolated from adult studies but requires consistent postmarketing long\u2010term follow\u2010up.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.42534","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:10:11Z","timestamp":1681729811000},"page":"1856-1866","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design"],"prefix":"10.1002","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-6472","authenticated-orcid":false,"given":"Laura E.","family":"Schanberg","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine  Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily (Yeruk)","family":"Mulugeta","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center  Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6237-4575","authenticated-orcid":false,"given":"Robert A.","family":"Colbert","sequence":"additional","affiliation":[{"name":"Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Delgaizo","sequence":"additional","affiliation":[{"name":"CARRA, Inc.  Washington DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"Gastonguay","sequence":"additional","affiliation":[{"name":"Metrum Research Group  Tariffville Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Glaser","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Imundo","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center  Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn H.","family":"Leu","sequence":"additional","affiliation":[{"name":"Janssen Research and Development  Spring House Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-768X","authenticated-orcid":false,"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  New Brunswick New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-3702","authenticated-orcid":false,"given":"Peter A.","family":"Nigrovic","sequence":"additional","affiliation":[{"name":"Division of Immunology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School and Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Department of Medicine Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-6134","authenticated-orcid":false,"given":"Nikolay P.","family":"Nikolov","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-2458","authenticated-orcid":false,"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, NIH  Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-3136","authenticated-orcid":false,"given":"Rebecca","family":"Rothwell","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrahas","family":"Sahajwalla","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renu","family":"Singh","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Sinha","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, One Health Plaza  East Hanover NJ 07936 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn L.","family":"Yancey","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Yao","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4060"},{"key":"e_1_2_9_3_1","unstructured":"Section 505B(e)(1) of the Food Drug & Cosmetic Act 21 USC 355c(e)(1) and Section 505B (a)(1) of the Food Drug & Cosmetic Act Pub L No. 108\u2013155 117 Stat 1936(2003)."},{"key":"e_1_2_9_4_1","unstructured":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. URL:https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CONSLEG:2006R1901:20070126:EN:PDF."},{"key":"e_1_2_9_5_1","first-page":"59","article-title":"Specific requirements on content and format labeling for human prescription drugs: revision of \u201cpediatric use\u201d subsection in the labeling: final rule","author":"US Department of Health and Human Services, Food and Drug Administration","year":"1994","journal-title":"Fed Regist"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-20195-0_11"},{"key":"e_1_2_9_7_1","unstructured":"ICH E11A draft guideline (Apr 2022) on pediatric extrapolation. URL:https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_Document_Step2_Guideline_2022_0404_0.pdf."},{"key":"e_1_2_9_8_1","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner HI","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_9_9_1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_9_10_1","first-page":"189","article-title":"Prognosis in Still's disease","volume":"9","author":"Ansell BM","year":"1959","journal-title":"Bull Rheum Dis"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.37.2.107"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00590-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2013.06.002"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24529"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.30.2.121"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22173"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180168"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199909)42:9<1843::AID-ANR8>3.0.CO;2-M"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27657"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27424"},{"key":"e_1_2_9_21_1","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP).Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis.2015."},{"key":"e_1_2_9_22_1","unstructured":"EMA Assessment Report for Simponi Dec2018. URL:https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/simponi\u2010h\u2010c\u2010992\u2010x\u20100083\u2010g\u2010epar\u2010assessment\u2010report\u2010extension_en.pdf."},{"key":"e_1_2_9_23_1","unstructured":"HUMIRA [package insert].North Chicago (IL): Abb Vie. URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf."},{"key":"e_1_2_9_24_1","unstructured":"ORENCIA [package insert].Princeton (NJ): Bristol\u2010Myers Squibb. URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125118s209lbl.pdf."},{"key":"e_1_2_9_25_1","unstructured":"ACETEMRA USPI [package insert].South San Francisco (CA): Genentech. URL:https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261602"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2218"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2498-1"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24044"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160"},{"key":"e_1_2_9_32_1","unstructured":"Humira summary of product characteristics. URL:https:\/\/www.medicines.org.uk\/emc\/product\/9080\/smpc."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0363-5"},{"key":"e_1_2_9_34_1","unstructured":"CDRH\/CBER guidance on Bayesian statistics. URL:https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/guidance\u2010use\u2010bayesian\u2010statistics\u2010medical\u2010device\u2010clinical\u2010trials."},{"key":"e_1_2_9_35_1","unstructured":"NDA\/BLA multi\u2010disciplinary review and evaluation for IV Benlysta in children with SLE. URL:https:\/\/www.fda.gov\/media\/127912\/download."},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012445206"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41390"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0160-6"},{"key":"e_1_2_9_39_1","unstructured":"Externally\u2010led Juvenile Idiopathic Arthritis Patient\u2010Focused Drug Development Meeting Report. URL:https:\/\/www.arthritis.org\/getmedia\/25118249\u2010ea68\u201045b5\u2010bfe4\u2010c20904ddc32c\/FINAL\u2010JIA\u2010PFDD.pdf."},{"key":"e_1_2_9_40_1","first-page":"360","article-title":"Sulfasalazine therapy for juvenile rheumatoid arthritis","volume":"23","author":"Imundo LF","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041810"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.212"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40466"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab047"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab021"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01255-1"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:15:12Z","timestamp":1759932912000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/art.42534"],"URL":"https:\/\/doi.org\/10.1002\/art.42534","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}